Drug Profile
Taurolidine - Geistlich
Alternative Names: PerioSept; TaurolinLatest Information Update: 26 Apr 2022
Price :
$50
*
At a glance
- Originator Geistlich
- Class Alkanesulfonic acids; Antibacterials; Antineoplastics; Thiadiazines
- Mechanism of Action Lipopolysaccharide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Empyema; Peritonitis
- Phase II Colorectal cancer
- No development reported Periodontitis
- Discontinued Septic shock
Most Recent Events
- 26 Apr 2022 No development reported - Phase-II for Periodontitis (Adjunctive treatment) in USA (IV) (NDR batch 22)
- 25 Sep 2020 Geistlich completes a phase II trial in Periodontitis (Adjunctive treatment) in USA (NCT04093895)
- 26 Aug 2019 Phase-II clinical trials in Periodontitis (Adjunctive treatment) in USA (IV) (NCT04093895)